In summary, this candidate gene study revealed that candidate functional polymorphisms at RLN3, RXFP3, RXFP4, RLN2, and RXFP1 had no significant effects on the outcomes of MDD, atypical depression, anxiety, and metabolic syndrome. The gene discussed is RLN2; the disease is major depressive disorder.